Zydus Lifesciences’ Sentynl Gets FDA Nod for ZYCUBO® in Menkes Disease

FDA Approval Milestone
 
Sentynl Therapeutics Inc., a U.S. subsidiary of Zydus Lifesciences, received FDA approval for ZYCUBO® (copper histidinate) to treat Menkes disease

First & Only Therapy
 
ZYCUBO® is now the first and only approved treatment for the rare and fatal pediatric genetic disorder Menkes disease in the U.S

Hope for Patients & Families

Approval provides a treatment option where none existed before, offering improved survival outcomes and quality of life

 Click Here

Scientific Backing

ZYCUBO® showed statistically significant survival improvement and is designed to restore copper levels in affected patients

With Our Subscription Plans

Open demat account in 5 minutes*

 Open Demat A/C G-L92HWH8MZR